Fox Chase Cancer Center News

PHILADELPHIA (July 1, 2020)—In a recent study, researchers at Fox Chase Cancer Center found that factors other than just age can be useful in determining courses of treatment for older patients with locally advanced rectal cancer.

PHILADELPHIA (June 29, 2020)—Researchers at Fox Chase Cancer Center recently conducted a study analyzing the impact of sun exposure and tanning patterns on gene mutations in patients with advanced melanoma. Those who experienced blistering sunburn had a higher number of gene mutations in their tumors compared to those who did not experience blistering sunburn.

PHILADELPHIA (June 25, 2020) – The Accreditation Council for Graduate Medical Education (ACGME) review committee stated that the program “demonstrated outstanding compliance with the ACGME’s Program Requirements and/or Institutional Requirements.” ACGME would not require a site visit for the next 10 years, the longest duration allowed by the ACGME.

PHILADELPHIA (June 25, 2020)—Survival rates for Black patients were worse than those for white patients being treated for head and neck cancer even when they had access to the same care. The researchers said the disparities could be explained by biological differences between the two groups.

PHILADELPHIA (June 24, 2020) – Fox Chase Cancer Center announces the hiring of Weier Li, MD, who will join the Department of Diagnostic Imaging as a full time body imager. Li will join Fox Chase as an assistant professor.

PHILADELPHIA (June 22, 2020)—Carolyn Y. Fang, PhD, was recently awarded a grant for the first large-scale study evaluating a method that allows Asian American women to collect their own samples, which can then be tested for the presence of the human papilloma virus (HPV). Fang will be conducting the research with Grace X. Ma, PhD, multiple principal investigator for the study.

PHILADELPHIA (June 18, 2020)—In a recent study, researchers at Fox Chase Cancer Center found that muscle-invasive bladder cancer patients with specific gene mutations have better survival outcomes when treated with chemotherapy before surgery. The five-year survival rate for patients with at least one mutation was 85 percent, compared to 45 percent for patients without a mutation.

PHILADELPHIA (June 17, 2020) – The Fox Chase-Temple University Hospital Bone Marrow Transplant Program has been reaccredited for adult allogeneic and autologous hematopoietic progenitor cell transplantation, peripheral blood cellular therapy product collection, and cellular therapy product processing with minimal manipulation. Also included is a new accreditation for immune effector cells.